225 related articles for article (PubMed ID: 34992118)
1. Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study).
Colomer-Carbonell A; Sanabria-Mazo JP; Hernández-Negrín H; Borràs X; Suso-Ribera C; García-Palacios A; Muchart J; Munuera J; D'Amico F; Maes M; Younger JW; Feliu-Soler A; Rozadilla-Sacanell A; Luciano JV
BMJ Open; 2022 Jan; 12(1):e055351. PubMed ID: 34992118
[TBL] [Abstract][Full Text] [Related]
2. Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia.
Naik H; Cooke E; Boulter T; Dyer R; Bone JN; Tsai M; Cristobal J; McKay RJ; Song X; Nacul L
BMJ Open; 2024 May; 14(5):e085272. PubMed ID: 38740499
[TBL] [Abstract][Full Text] [Related]
3. Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial.
Bruun KD; Amris K; Vaegter HB; Blichfeldt-Eckhardt MR; Holsgaard-Larsen A; Christensen R; Toft P
Trials; 2021 Nov; 22(1):804. PubMed ID: 34781989
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, cost-utility and physiological effects of Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment for Depression (BATD) in patients with chronic low back pain and depression: study protocol of a randomised, controlled trial including mobile-technology-based ecological momentary assessment (IMPACT study).
Sanabria-Mazo JP; Forero CG; Cristobal-Narváez P; Suso-Ribera C; García-Palacios A; Colomer-Carbonell A; Pérez-Aranda A; Andrés-Rodríguez L; McCracken LM; D'Amico F; Estivill-Rodríguez P; Carreras-Marcos B; Montes-Pérez A; Comps-Vicente O; Esteve M; Grasa M; Rosa A; Cuesta-Vargas AI; Maes M; Borràs X; Edo S; Sanz A; Feliu-Soler A; Castaño-Asins JR; Luciano JV
BMJ Open; 2020 Jul; 10(7):e038107. PubMed ID: 32709656
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
7. Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial.
Paula TMH; Castro MS; Medeiros LF; Paludo RH; Couto FF; Costa TRD; Fortes JP; Salbego MO; Behnck GS; Moura TAM; Tarouco ML; Caumo W; Souza A
Braz J Anesthesiol; 2023; 73(4):409-417. PubMed ID: 35988815
[TBL] [Abstract][Full Text] [Related]
8. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
9. Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn's disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study.
Paulides E; Lie MRKL; van der Woude CJ
BMJ Open; 2022 Apr; 12(4):e058358. PubMed ID: 35396307
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder.
Plank JR; Glover SC; Moloney BD; Hoeh NR; Sundram F; Sumner RL; Muthukumaraswamy S; Lin JC
Trials; 2022 Sep; 23(1):822. PubMed ID: 36175917
[TBL] [Abstract][Full Text] [Related]
11. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.
Younger J; Noor N; McCue R; Mackey S
Arthritis Rheum; 2013 Feb; 65(2):529-38. PubMed ID: 23359310
[TBL] [Abstract][Full Text] [Related]
12. Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.
Matsuoka H; Ishiki H; Iwase S; Koyama A; Kawaguchi T; Kizawa Y; Morita T; Matsuda Y; Miyaji T; Ariyoshi K; Yamaguchi T
BMJ Open; 2017 Aug; 7(8):e017280. PubMed ID: 28851798
[TBL] [Abstract][Full Text] [Related]
13. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
15. Low dose naltrexone for induction of remission in Crohn's disease.
Segal D; Macdonald JK; Chande N
Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
[TBL] [Abstract][Full Text] [Related]
16. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial.
Due Bruun K; Christensen R; Amris K; Vaegter HB; Blichfeldt-Eckhardt MR; Bye-Møller L; Holsgaard-Larsen A; Toft P
Lancet Rheumatol; 2024 Jan; 6(1):e31-e39. PubMed ID: 38258677
[TBL] [Abstract][Full Text] [Related]
17. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
18. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
19. Multiple Interventions for Diabetic Foot Ulcer Treatment Trial (MIDFUT): study protocol for a randomised controlled trial.
Brown S; Nixon J; Ransom M; Gilberts R; Dewhirst N; McGinnis E; Longo R; Game F; Bojke C; Chadwick P; Chandrasekar A; Chetter I; Collier H; Fernandez C; Homer-Vanniasinkam S; Jude E; Leigh R; Lomas R; Vowden P; Wason J; Sharples L; Russell D
BMJ Open; 2020 Apr; 10(4):e035947. PubMed ID: 32312727
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of mecobalamin (vitamin B
Sall Hansson K; Lindqvist G; Stening K; Fohlman J; Wojanowski A; Ponten M; Jensen K; Gerdle B; Elmqvist C
BMJ Open; 2023 Mar; 13(3):e066987. PubMed ID: 36997252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
